ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Biotechnology

Healthcare
$3.69 -3.51%

-$0.35 today

Market cap
$370.95M
Beta
0.83
P/E (TTM)
-4.8
EPS (TTM)
-$1.99
52W Low $6.66High $18.90

Volume 1.70M

Average 1.67M

SPRY Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

ARS Pharmaceuticals, Inc.NASDAQ: SPRY

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow dips below year-ago levels

Q1 FY2026 financing cash flow of $159K fell 78.1% year over year, behind the +42.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 85.9% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.

Context

  • Financing cash flow amounted to 124.1% of revenue in FY2025, up 42.9 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -78.1% toward the trailing-twelve-month pace of +42.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$159K-85.9% QoQ
Last fiscal yearDec 2025
$104.6M+44.5% YoY
LTMMar 2026
$104.03M+42.8% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-78.1%——
1 year+44.5%——
3-year CAGR-18.1%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
104.6M USD
Year-over-year change
+44.5%
4-year CAGR
+18.4%

Financing Cash Flow vs competitors

How SPRY compares with its peers on the latest reported figures

  • SPRY's LTM Mar 2026 financing cash flow of $104.03M is the 2nd largest of the 4 companies compared; the peer median is $86.39M.
  • Its year-over-year change of +42.8% is the lowest of 4, against a peer median of +310.5%.
  • Financing cash flow amounts to 105.1% of revenue for SPRY, versus a peer median of 77.3%.
SPRY Competitors Peer median
Financing Cash Flow for SPRY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNKDMannKind CorporationLTM Mar 2026$278.74M +310.5%+145.1%77.3%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$104.03M +42.8%-18.1%105.1%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$86.39M +284.0%+107.0%171.9%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$5.69M +363.0%-55.3%1.8%
Peer median (excluding SPRY) $86.39M+310.5%+107.0%77.3%

Competitors are the stored peer set for SPRY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.24M)(34.68M)(54.37M)8M(171.3M)
Depreciation & Amortization213K319K73K(7.18M)1.37M
Deferred Income Tax00000
Stock-Based Compensation2.83M5.84M9.24M14.53M22.1M
Change in Working Capital(356K)(12.75M)(7.33M)(1.81M)(20M)
Accounts Receivables000(8.18M)(17.21M)
Inventory000(5.95M)(21.99M)
Accounts Payables0(10.29M)(2.78M)16.43M18.88M
Other Working Capital(356K)(2.47M)(4.55M)(4.12M)306K
Other Non-Cash Items(4K)1.2M(6.88M)0(3.03M)
Operating Cash Flow(17.56M)(40.08M)(59.27M)13.55M(170.87M)
Capital Expenditures(55K)(199K)(175K)(563K)(339K)
Acquisitions (Net)00000
Purchases of Investments00(272.01M)(356.04M)(242.03M)
Sales of Investments00185M258M307M
Other Investing Activities000(7.5M)(7.86M)
Investing Cash Flow(55K)(199K)(87.18M)(106.1M)56.77M
Debt Repayment(1.82M)(8.68M)069.38M96.26M
Common Stock Issued169K570K6.9M3.02M5.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0198.84M002.66M
Financing Cash Flow53.16M190.73M6.9M72.4M104.6M
Effect of Forex Changes00000
Net Change in Cash35.54M150.46M(139.55M)(20.15M)(9.5M)
Free Cash Flow(17.62M)(40.28M)(59.44M)12.99M(171.21M)

ARS Pharmaceuticals, Inc.

NASDAQ:SPRY

Intrinsic Alpha fair value

Locked

Current Price

$3.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.